729-46-4

Basic information

• Product Name: 4,4'-(dithiodicarbonothioyl)dimorpholine
• Synonyms: 4,4'-(dithiodicarbonothioyl)dimorpholine;Morpholine, 4,4-(dithiodicarbonothioyl)bis-;Bis(morpholinocarbonothioyl) persulfide
• CAS NO: 729-46-4
• Molecular Formula: C₁₀H₁₆N₂O₂S₄
• Molecular Weight: 324.50624
• EINECS: 211-980-6
• Mol File: 729-46-4.mol
• Article Data: 19

Chemical Properties

• Melting Point: 136-137 °C
• Boiling Point: 466.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.4302 (rough estimate)
• Refractive Index: 1.5650 (estimate)
• PKA: 0.58±0.20(Predicted)
• CAS DataBase Reference: 4,4'-(dithiodicarbonothioyl)dimorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4'-(dithiodicarbonothioyl)dimorpholine(729-46-4)
• EPA Substance Registry System: 4,4'-(dithiodicarbonothioyl)dimorpholine(729-46-4)

Safety Data

• Hazardous Substances Data: 729-46-4(Hazardous Substances Data)

Usage

Uses

JX 06 is a covalent inhibitor of Potent Covalent Pyruvate Dehydrogenase Kinase (PDK).

Upstream product

• 5327-10-6 morpholinium morpholine-1-carbodithioate 
• 873-58-5 sodium N-morpholinocarbamodithioate 
• 121-30-2 chloraminophenamide 
• 138-39-6 4-homosulfanilamide 
• 53297-68-0 4-amino-3-chlorobenzenesulfonamide 
• 16840-26-9 3-sulfanilylamino-benzenesulfonic acid amide 
• 2368-84-5 4-amino-3-fluorobenzenesulfonamide 
• 53297-69-1 4-amino-3-bromo-benzenesulfonamide 
• 60154-06-5 4-amino-3-iodo-benzenesulfonic acid amide 
• 149249-72-9 dorzolamide 
• 216885-22-2 5-[(E)-4-Amino-benzenesulfonylimino]-4-methyl-4,5-dihydro-[1,3,4]thiadiazole-2-sulfonic acid amide 
• 217972-52-6 3-amino-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)propanamide 
• 35303-76-5 4-(2-aminoethyl)benzenesulfonamide 
• 547-52-4 4-amino-N-[4-(aminosulfonyl)phenyl]-benzenesulfonamide 

Downstream Products

• 5327-10-6 morpholinium morpholine-1-carbodithioate 
• 36903-85-2 (cyclohexylamino)morpholin-4-ylmethane-1-thione 
• 15093-54-6 N-phenyl-1-morpholinethiocarbamide 
• 25180-84-1 N-benzylmorpholine-4-carbothioamide 
• 77478-35-4 4-(trifluoromethyl)morpholine 
• 873-58-5 sodium N-morpholinocarbamodithioate 
• 147723-53-3 Morpholine-4-carbodithioic acid 2-oxo-cyclohexyl ester 
• 147723-54-4 2-(4'-Morpholino-thiocarbonylthio)cyclopentanon 
• 725-33-7 morpholine-4-carbothioic acid thio anhydride 
• 1013-93-0 di-morpholin-4-ylmethane-1-thione 

Relevant articles and documents

Carbonic anhydrase inhibitors: Synthesis of N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV

Several aromatic/heterocyclic sulfonamides possessing free amino, imino or hydrazino moieties were transformed into the corresponding N-morpholylthiocarbonylsulfenyl derivatives, by reaction with N-morpholyldithiocarbamate in the presence of oxidizing age

Continuous-flow step-economical synthesis of thiuram disulfidesviavisible-light photocatalytic aerobic oxidation

A continuous-flow photocatalytic synthesis of the industrially important thiuram disulfides has been developed, utilizing O2as the oxidant and Eosin Y as the photoredox catalyst. This highly atom- and step-economical method features much reduced reaction time as well as excellent product yield and purity, making it a sustainable and potentially scalable process for industrial production.

Disulfiram as a potent metallo-β-lactamase inhibitor with dual functional mechanisms

We report a promising NDM-1 inhibitor, disulfiram, which can covalently bind to NDM-1 by forming an S-S bond with the Cys208 residue. Its copper-containing metabolite in vivo, Cu(DTC)2, also inactivated NDM-1 through oxidizing the Zn(ii) thiolate site of the enzyme, therefore exhibiting dual functional inhibitory potential against B1 and B2 subclass MβLs.

Pyruvate dehydrogenase kinase inhibitor and application thereof

The invention provides a pyruvate dehydrogenase kinase inhibitor and an application thereof, specifically a compound as shown in a formula I described in the specification or pharmaceutically acceptable salts thereof. The compound has excellent effects of inhibiting pyruvate dehydrogenase kinase activity and resisting tumors. The invention also provides a pharmaceutical composition containing the compound provided by the invention and the application thereof in the aspect of inhibiting pyruvate dehydrogenase kinase.